en · de · es · fr · pt
sr9009-notes.peptides6088.com › Blog › Analytical Detection And Laboratory Handling — Questions and Answers

Analytical Detection And Laboratory Handling — Questions and Answers

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-23 · Blog

Stenabolic raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Sr9009 at a glance

PropertyValueNotes
AppearanceOff-white to pale yellow solidVisual description varies with purity and source
SolubilitySoluble in DMSO and ethanol; poorly soluble in waterOrganic stock solutions are common in research
Typical storage-20 °C, desiccated, protected from lightAvoid repeated freeze-thaw cycles
Typical analytical methodLC-MS or HPLC-UVReference standards are needed for quantification
Molar massApproximately 437.9 g/molCalculated from the reported free-base formula

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Related pages on this site

Reference notes

=== United States === One entrepreneur who was quick to spot the advantages of machine-made cigarettes was James Buchanan Duke. Previously a producer of smoking tobacco only, his firm, W. Duke & Sons & Co., entered the cigarette industry in the early 1880s. After installing two Bonsack machines, Duke spent heavily on advertising and sales promotion, and by 1889 his was the largest cigarette manufacturer in the country. The new Bonsack machines were of decisive importance in the rapid, cheap manufacture of all tobacco products but one. Cigars needed slow, laborious hand rolling and were produced in hundreds of small workshops, especially in New York City. In 1890 Duke and the other four major cigarette companies combined to form the American Tobacco Company, a firm that dominated the market and used aggressive tactics on hundreds of small competitors until they sold out to the firm. It was also called the "Tobacco Trust". The trust soon expanded its operations to include cigars, smoking, chewing tobacco and snuff. Among the companies drawn into this organization were the plug manufacturers Liggett & Myers and R. J. Reynolds Tobacco Company, which at the time produced twist and flat plug, and P. Lorillard, an old-line manufacturer of snuff. By 1910 the trust produced 86% of all cigarettes produced in the United States, and 75% to 95% of other forms, but only 14% of cigars produced in the country. At the start of the 20th century, the per capita annual consumption in the U.S.

== Chemical designation == This compound belongs to a class of experimental compounds known as N-acyl-alpha-amino acids and their derivatives. These are compounds containing an alpha-amino acid (or its derivative) with an acyl group on the terminal nitrogen atom.

The U.S. National Institute of Standards and Technology investigated the collapses of the Twin Towers and 7 WTC. The investigations examined why the buildings collapsed and what fire protection measures were in place, and evaluated how fire protection systems might be improved in future construction. The investigation into the collapse of 1 WTC and 2 WTC was concluded in October 2005 and that of 7 WTC was completed in August 2008. NIST found that the fireproofing on the Twin Towers' steel infrastructures was blown off by the initial impact of the planes and that had this not occurred, the towers likely would have remained standing. A 2007 study of the north tower's collapse published by researchers at Purdue University determined that since the plane's impact had stripped off much of the structure's thermal insulation, the heat from a typical office fire would have softened and weakened the exposed girders and columns enough to initiate the collapse regardless of the number of columns cut or damaged by the impact. The director of the original investigation stated that "the towers did amazingly well. The terrorist aircraft didn't bring the buildings down; it was the fire that followed. It was proven that you could take out two-thirds of the columns in a tower and the building would still stand." The fires weakened the trusses supporting the floors, making the floors sag. The sagging floors pulled on the exterior steel columns causing the exterior columns to bow inward.

A miniature mass spectrometer (MMS) is a type of mass spectrometer (MS) which has small size and weight and can be understood as a portable or handheld device. What it means to be portable and a set of criteria by which portable and miniature mass spectrometers can be assessed have been discussed in detail. Current lab-scale mass spectrometers however, usually weigh hundreds of pounds and can cost on the range from thousands to millions of dollars. One purpose of producing MMS is for in situ analysis. This in situ analysis can lead to much simpler mass spectrometer operation such that non-technical personnel like physicians at the bedside, firefighters in a burning factory, food safety inspectors in a warehouse, or airport security at airport checkpoints, etc. can analyze samples themselves saving the time, effort, and cost of having the sample run by a trained MS technician offsite. Although, reducing the size of MS can lead to a poorer performance of the instrument versus current analytical laboratory standards, MMS is designed to maintain sufficient resolutions, detection limits, accuracy, and especially the capability of automatic operation. These features are necessary for the specific in-situ applications of MMS mentioned above.

== History == The US Food and Drug Administration (FDA) approved serdexmethylphenidate/dexmethylphenidate based on evidence from one clinical trial of 150 participants with attention deficit hyperactivity disorder 6 to 12 years of age (Study 1). The four-week trial was conducted at five sites in the United States. The safety and tolerability of serdexmethylphenidate/dexmethylphenidate was examined in an open-label trial of 238 participants with attention deficit hyperactivity disorder 6 to 12 years of age (Study 2). The 12-month trial was conducted at 18 sites in the United States.

Sources: en.wikipedia.org

Notes from published material

Federal level policies include Healthy, Hunger-Free Kids Act, the Supplemental Nutrition Assistance Program Education program, and Safe Routes to School funding. (PMC) The Healthy, Hunger-Free Kids Act of 2010 helped provide nutrition standards for meals and drinks through a variety of programs affecting 50 million children daily at 99,000 schools. The risk of obesity declines each year for children in poverty. The results suggest that the Healthy, Hunger-Free Kids Act's science-based nutritional standards should be maintained to support healthy growth, especially among children living in poverty, according to Health Affairs. The Supplemental Nutrition Assistance Program Education program (SNAP-Ed) is an approach that helps people be healthy and active. This program teaches people how to manage their SNAP dollars, how to shop and cook for healthy food, and how to stay active. They partner with state and local organizations to meet people where they are located. Some of their efforts include nutrition education classes, policy improvement, social media campaigns, and more. SNAP-Ed directly and sustainably improves food security either with or without food assistance. Nutrition education is critical to improving food security in the U.S. low-income population. Safe Routes to School is an initiative that makes it safe and convenient for children to walk and bicycle to and from school. The goal is to get more children to improve kids' safety, increase their health and physical activity, and to get more children walking and bicycling to school.

== Sports == Russian Paralympic Committee RPC, the IPC code used for Russian Olympic Committee athletes: Russian Paralympic Committee athletes at the 2020 Summer Paralympics Russian Paralympic Committee athletes at the 2022 Winter Paralympics

=== Career and polymer science === Flory's earliest work in polymer science was in the area of polymerization kinetics at the DuPont Experimental Station. In condensation polymerization, he challenged the assumption that the reactivity of the end group decreased as the macromolecule grew, and by arguing that the reactivity was independent of the size, he was able to derive the result that the number of chains present decreased with size exponentially. In addition polymerization, he introduced the important concept of chain transfer to improve the kinetic equations and remove difficulties in understanding the polymer size distribution. In 1938, after Carothers' death, Flory moved to the Basic Science Research Laboratory at the University of Cincinnati. There he developed a mathematical theory for the polymerization of compounds with more than two functional groups and the theory of polymer networks or gels. This led to the Flory-Stockmayer theory of gelation, which was equivalent to percolation on the Bethe lattice and represents the first paper in the percolation field. In 1940 he joined the Linden, NJ laboratory of the Standard Oil Development Company where he developed a statistical mechanical theory for polymer mixtures. In 1943 he left to join the research laboratories of Goodyear as head of a group on polymer fundamentals. In the Spring of 1948 Peter Debye, then chairman of the chemistry department at Cornell University, invited Flory to give the annual Baker Lectures. He then was offered a position with the faculty in the Fall of the same year.

There has been a growing interest in the application of ion chromatography in the analysis of pharmaceutical drugs. Ion chromatography is used in different aspects of product development and quality control testing. For example, ion chromatography is used to improve stabilities and solubility properties of pharmaceutical active drugs molecules as well as used to detect systems that have higher tolerance for organic solvents. Ion chromatography has been used for the determination of analytes as a part of a dissolution test. For instance, calcium dissolution tests have shown that other ions present in the medium can be well resolved among themselves and also from the calcium ion. Therefore, ion chromatography has been employed in drugs in the form of tablets and capsules in order to determine the amount of drug dissolve with time. Ion chromatography is also widely used for detection and quantification of excipients or inactive ingredients used in pharmaceutical formulations. Detection of sugar and sugar alcohol in such formulations through ion chromatography has been done due to these polar groups getting resolved in ion column. Ion chromatography methodology also established in analysis of impurities in drug substances and products. Impurities or any components that are not part of the drug chemical entity are evaluated and they give insights about the maximum and minimum amounts of drug that should be administered in a patient per day.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

What is known about its stability?

The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.

Why does solubility matter?

Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network